INPULSIS trials

October 26, 2017October 26, 2017

Early Analysis of Ofev in INPULSIS-ON Trial Shows Long-Term Effectiveness in Treating IPF

News

The therapy Ofev (nintedanib) was shown to slow down the progression of idiopathic pulmonary fibrosis (IPF) through 96 weeks, regardless of a patient’s lung disease severity at the beginning of the study ... Read more

October 24, 2017October 24, 2017

Ofev Improves IPF Patients’ Lung Function Over the Long Term, Trial and Extension Show

Idiopathic Pulmonary Fibrosis, News

Long-term treatment with Boehringer Ingelheim‘s Ofev (nintedanib) improved the lung function and reduced the flare-ups of people with idiopathic pulmonary fibrosis, results of a Phase 2 clinical trial and its extension show. ... Read more

June 28, 2016June 28, 2016

Analysis Shows IPF Treatment OFEV (Nintedanib) Effective in Test, Broader Criteria

Idiopathic Pulmonary Fibrosis, News

The latest analysis of Inpulsis clinical trials demonstrated that Ofev (nintedanib) for idiopathic pulmonary fibrosis slows the disease progression and that treatment results are similar using broader diagnostic criteria than required. The data was ... Read more

May 18, 2016May 18, 2016

Efficacy and Safety of Ofev (Nintedanib) as IPF Treatment Supported by New Analyses

Idiopathic Pulmonary Fibrosis, News

Boehringer Ingelheim Pharmaceuticals presented 12 idiopathic pulmonary fibrosis (IPF)-related abstracts at the recent American Thoracic Society (ATS) 2016 Annual Conference, including further analyses of its INPULSIS clinical trial program, which added to the ... Read more

February 29, 2016May 13, 2016

Ofev (Nintedanib) Slows IPF Disease Progression, According to Analysis of Studies

Idiopathic Pulmonary Fibrosis, News

An analysis of the Phase II TOMORROW trial and two Phase III INPULSIS trials (INPULSIS-1 and INPULSIS-2), analyzing the safety and efficacy outcomes for Ofev (nintedanib, developed by Boehringer Ingelheim), revealed that ... Read more